Nuvectis Pharma, Inc.
NVCT
$9.24
$0.819.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -27.84% | 5.65% | 29.38% | 22.42% | -3.01% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.56% | -6.48% | 2.29% | 32.84% | -7.56% |
| Change in Net Operating Assets | 85.84% | 70.23% | -60.77% | -78.37% | 30.38% |
| Cash from Operations | 4.22% | 35.97% | 25.89% | 26.03% | 8.77% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 246.42% | 338.73% | 32.19% | -87.43% | 590.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -745.10% | -875.00% | 88.56% | 89.48% | 66.00% |
| Cash from Financing | 230.17% | 317.56% | 107.25% | -87.35% | 1,763.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,252.37% | 146.51% | 62.73% | -114.76% | 107.47% |